Breast Cancer

SITC's Cancer Immunotherapy Guidelines program is a
collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as  well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The Breast Cancer Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with breast cancer. In March 2019, accelerated approval was granted by the U.S. FDA for the checkpoint inhibitor atezolizumab in combination with chemotherapy for the treatment of PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC)—the first immuno-oncology agent approval for this disease setting. Trials are ongoing evaluating other immunotherapeutic agents as monotherapies and combination regimens for the treatment of TNBC and other breast cancer subtypes. Reflecting the evolving therapeutic landscape, SITC is currently developing a breast cancer CPG with topics including selection of appropriate immunotherapeutic regimens, companion diagnostics, recognition and management of adverse events, and patient quality of life considerations.

SITC Breast Cancer Immunotherapy Guideline Expert Panel

Sylvia Adams, MD – New York University Langone Perlmutter Cancer Center

Ashley Cimino-Mathews, MD – Johns Hopkins Hospital

Mary L. Disis, MD, FACP – University of Washington

Margaret E. Gatti-Mays, MD, MPH – The Ohio State University

Alice Y. Ho, MD – Massachusetts General Hospital

Kevin Kalinsky, MD, MS – Emory University

Heather L. McArthur, MD, MPH – Cedars-Sinai Medical Center

Elizabeth A. Mittendorf MD, PhD – Dana-Farber Cancer Institute and Brigham & Woman's Cancer Institute

Rita Nanda, MD – University of Chicago

David B. Page, MD – Earle A. Chiles Research Institute

Hope S. Rugo, MD, FASCO – UCSF Helen Diller Family Comprehensive Care Center

Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

Hatem Soliman, MD – Moffitt Cancer Center

Patricia Spears (Patient Advocate) – UNC School of Medicine Lineberger Comprehensive Cancer Center

Sara M. Tolaney, MD, MPH – Dana-Farber Cancer Institute